Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Oncotarget|January 10, 2018
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancersGiulia Bon, Rossella Loria, Carla Azzurra Amoreo, et al.Oncogene|July 8, 2018
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistanceRossella Loria, Valentina Laquintana, Giulia Bon, et al.International Journal of Molecular Sciences|August 21, 2019
H19-Dependent Transcriptional Regulation of β3 and β4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate CancerLorenza Bacci, Aurora Aiello, Cristian Ripoli, et al.Journal of Experimental & Clinical Cancer Research : CR|April 20, 2022
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanomaRossella Loria, Valentina Laquintana, Stefano Scalera, et al.Journal of Experimental & Clinical Cancer Research : CR|July 28, 2023
The new world of RNA diagnostics and therapeuticsGiovanni Blandino, Roberto Dinami, Marco Marcia, et al.Frontiers in Oncology|May 1, 2020
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.Frontiers in Oncology|July 14, 2020
Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.Pageof 2